NCT01034982已完成1 期
A Phase I Open-label, Single-centre, Two Cohort Crossover Study to Assess the Relative Bioavailability After Oral Administration of AZD9668 Free Base Dosed as a Suspension Compared to AZD9669 Tosylate Salt Dosed as a Tablet
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Relative bioavailability (Frel): to assess the relative systemic bioavailability after oral administration of the free base of AZD9668 dosed as a suspension compared to the tosylate salt of AZD9668 dosed as a tablet formulation at two dose levels.
研究概览
简要总结
The study is designed to investigate the pharmacokinetic behaviour of the free base formulation of AZD9668. The study will compared the relative bioavailability of the free base formulation at two different dose levels compared to the tosylate salt formulation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provision of informed consent prior to any study-specific procedures
- •female subjects may be of non-child bearing potential (i.e. post menopausal or surgically sterile).
- •Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2 calculated from height and weight at the screening visit; minimum weight 50 kg.
- •Clinically normal physical and laboratory findings as judged by the investigator, including negative test results for drug-of-abuse, alcohol, cotinine and negative test results for Hepatitis B surface antigen, antibodies to Hepatitis C virus and antibodies to HIV-1/2 at the screening visit
- •Be a none smoker or ex-smoker who has stopped smoking for >6 months prior to visit 2 (pre-entry)
排除标准
- •Any clinically significant disease or disorder (eg infections/viral disease, cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment), which in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the absorption, distribution, metabolism and excretion of drugs.
- •Any clinically relevant abnormal findings in physical examination, vital signs, clinical chemistry, haematology, urinalysis, which, in the opinion of the investigator, may put the subject at risk because of his/her participation in the study
- •History of cardiac arrhythmia
研究组 & 干预措施
1
Experimental
tosylate salt tablet
干预措施: AZD9668 (Drug)
2
Experimental
free suspension
干预措施: AZD9668 (Drug)
3
Experimental
tosylate salt tablet
干预措施: AZD9668 (Drug)
4
Experimental
free suspension
干预措施: AZD9668 (Drug)
结局指标
主要结局
Relative bioavailability (Frel): to assess the relative systemic bioavailability after oral administration of the free base of AZD9668 dosed as a suspension compared to the tosylate salt of AZD9668 dosed as a tablet formulation at two dose levels.
时间窗: Frequent sampling occasions during the study
次要结局
- Safety variables (adverse events, blood pressure, pulse rate, 12-lead ECG, haematology, clinical chemistry and urinalysis)(Frequent sampling occasions during the study)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human SubjectsHealthyNCT05166096Rhoshan Pharmaceuticals Inc24
已完成
1 期
A preliminary open-labeled pharmacokinetic study to examine the effect of cilastatin on the prevention of acute kidney injury in cancer patients undergoing cisplatin-based chemotherapyon-small cell lung cancerJPRN-UMIN000030363Department of Applied Molecular Medicine, Kidney Research Center, Niigata University Graduate School of Medical and Dental Science9
已完成
1 期
A preliminary open-labeled pharmacokinetic study to examine the effect of cilastatin on the prevention of acute kidney injury in cancer patients undergoing cisplatin-based chemotherapyon small cell lung cancerJPRN-jRCTs031180329Saito Akihiko9
已完成
1 期
Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.Healthy VolunteersNCT02189733Ablynx, a Sanofi company24
已完成
1 期
Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive SubjectsPharmacokinetics and PharmacodynamicsNCT02576353INSYS Therapeutics Inc50